Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Database.

Annals of hepato-biliary-pancreatic surgery·2026
Same author

An Accessible Python Framework for Real-Time Magnetic Tweezers Microscope Control and Image Processing.

bioRxiv : the preprint server for biology·2025
Same author

Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer.

Cancer research communications·2025
Same author

Epigenetic Modulation, Intra-tumoral Microbiome and Immunity in Early Onset Colorectal Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Proteomic Profiling of Medullary Thyroid Cancer Identifies CAPN1 as a Key Regulator of NF1 and RET Fueled Growth.

Thyroid : official journal of the American Thyroid Association·2025
Same journal

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Molecular cancer therapeutics·2026
Same journal

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model.

Molecular cancer therapeutics·2026
Same journal

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib.

Molecular cancer therapeutics·2026
Same journal

Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

Molecular cancer therapeutics·2026
Same journal

Concurrent inhibition of ICMT and RAF/MEK suppresses RAC1P29S-driven MAPK-pathway-inhibitor resistance in BRAFV600E melanoma by regulating TAZ activity.

Molecular cancer therapeutics·2026
Same journal

Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models.

Molecular cancer therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

826

Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer.

Beiyuan Liang1, Misbah Khan1, Hayden Storts1

  • 1Department of Cancer Biology and Genetics, James Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio.

Molecular Cancer Therapeutics
|October 9, 2024
PubMed
Summary
This summary is machine-generated.

Riluzole, an ALS drug, boosts anti-tumor CD8+ T cells by activating the cGAS/STING pathway in colon cancer cells. This enhances anti-PD-1 therapy effectiveness, offering new hope for colorectal cancer treatment.

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

Related Experiment Videos

Last Updated: Jun 11, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

826
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Colorectal cancer is a leading cause of cancer death.
  • Current immunotherapies like anti-PD-1/PD-L1 have limited efficacy in many patients.
  • Novel therapeutic strategies are needed to improve colorectal cancer treatment outcomes.

Purpose of the Study:

  • To investigate the anti-tumor effects of riluzole in colorectal cancer.
  • To elucidate the underlying molecular mechanisms of riluzole's action.
  • To evaluate the potential of riluzole in combination with immune checkpoint inhibitors.

Main Methods:

  • Utilized syngeneic immune-competent mouse models of colon cancer.
  • Administered riluzole and assessed tumor growth and intratumoral CD8+ T cell infiltration.
  • Investigated the role of the cGAS/STING pathway and ATM in riluzole's mechanism of action.
  • Combined riluzole with anti-PD-1 therapy to evaluate synergistic effects.

Main Results:

  • Riluzole suppressed tumor growth and increased intratumoral CD8+ T cells in a CD8+ T cell-dependent manner.
  • Riluzole activated the cGAS/STING pathway in colon cancer cells, upregulating IFNβ and CXCL10.
  • Riluzole's effects were dependent on cGAS/STING activation and involved an ATM-mediated DNA damage response.
  • Combination therapy with riluzole and anti-PD-1 demonstrated enhanced anti-tumor efficacy compared to single agents.

Conclusions:

  • Riluzole activates tumor cell-intrinsic cGAS/STING innate immune responses.
  • Riluzole enhances CD8+ T cell infiltration and tumor suppression.
  • Riluzole shows promise as a sensitizer for anti-PD-1/PD-L1 therapies in colorectal cancer.